Ipsen phase 3 Bylvay trial in biliary atresia misses primary goal
Phase 3negativeBylvayNegative
AI Analysis
Summary
Ipsen's Bylvay failed to meet the primary objective in its Phase 3 trial for biliary atresia, a significant negative development for the program.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
Primary goal missed
Importance:8/10
Sentiment:
-0.85
Phase 3 failureprimary endpoint missedbiliary atresiaBylvay
Related Companies
Read the original article
Published by Seeking Alpha Healthcare on July 24, 2026 2:04 PM